Coherus Oncology
CHRS
146 hedge funds and large institutions have $1.47B invested in Coherus Oncology in 2019 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 46 increasing their positions, 39 reducing their positions, and 11 closing their positions.
695% more call options, than puts
Call options by funds: $8.59M | Put options by funds: $1.08M
273% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 11
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
25% more funds holding
Funds holding: 117 → 146 (+29)
18% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 39
1% more capital inflows, than outflows
Capital inflows: $214M | Capital outflows: $212M
2.97% less ownership
Funds ownership: 99.29% → 96.32% (-3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$41.9M |
| 2 |
Deerfield Management
New York
|
+$29.1M |
| 3 |
Rock Springs Capital Management
Baltimore,
Maryland
|
+$21M |
| 4 |
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$13.3M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$9.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$34.9M |
| 2 |
Rubric Capital Management (New York)
New York
|
-$33.7M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$13.8M |
| 4 |
Sofinnova Investments
Menlo Park,
California
|
-$13.5M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.1M |
CHRS Hedge Fund Activity: Q2 2019 in Review
146 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2019, worth a combined $1.47B — up 57% from $938M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new CHRS positions and 11 closed out — a net gain of 30 holders — while 46 added to existing stakes and 39 trimmed.
The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $41.9M. The largest seller was Citadel Advisors, cutting an estimated $34.9M.
- 146 institutional investors held Coherus Oncology (CHRS) as of Q2 2019, up from 117 in Q1 2019.
- Funds reported $1.47B of Coherus Oncology stock for Q2 2019, up 57% quarter-over-quarter.
- 41 funds opened new Coherus Oncology positions in Q2 2019 and 11 closed out, a net change of +30 holders.
- The largest Coherus Oncology buyer in Q2 2019 was Lord, Abbett & Co, an estimated $41.9M added.
- The largest Coherus Oncology seller in Q2 2019 was Citadel Advisors, an estimated $34.9M sold.
Based on aggregated 13F filings for Q2 2019.